Drug Type Small molecule drug |
Synonyms Giredestrant (USAN/INN), 吉瑞司群, GDC-49545 + [3] |
Target |
Action antagonists |
Mechanism ERs antagonists(Estrogen receptors antagonists) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |
Molecular FormulaC27H31F5N4O |
InChIKeyGQCXHIKRWBIQMD-AKJBCIBTSA-N |
CAS Registry1953133-47-5 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D11961 | - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| ER-positive/HER2-negative/ ESR1-mutated breast cancer | NDA/BLA | United States | 28 Feb 2026 | |
| Estrogen receptor positive breast cancer | Phase 3 | United States | 03 Aug 2022 | |
| Estrogen receptor positive breast cancer | Phase 3 | Japan | 03 Aug 2022 | |
| Estrogen receptor positive breast cancer | Phase 3 | Argentina | 03 Aug 2022 | |
| Estrogen receptor positive breast cancer | Phase 3 | Germany | 03 Aug 2022 | |
| Estrogen receptor positive breast cancer | Phase 3 | Greece | 03 Aug 2022 | |
| Estrogen receptor positive breast cancer | Phase 3 | Italy | 03 Aug 2022 | |
| Estrogen receptor positive breast cancer | Phase 3 | Singapore | 03 Aug 2022 | |
| Estrogen receptor positive breast cancer | Phase 3 | South Africa | 03 Aug 2022 | |
| Estrogen receptor positive breast cancer | Phase 3 | South Korea | 03 Aug 2022 |
Phase 2 | 92 | (Arm A) | jeyaskcxvw(xtvouzsboo) = imoxrojimw eufmfsuxvl (nkjoiplnuy, xnvffqgqbt - uwopeswujq) View more | - | 19 Mar 2026 | ||
(Arm B) | jeyaskcxvw(xtvouzsboo) = mjqadvhqno eufmfsuxvl (nkjoiplnuy, zdhwsewfrk - dgzvqrvcwj) View more | ||||||
Phase 3 | ER-positive/HER2-negative Breast Cancer HER2 Negative | ER Positive | 4,170 | Giredestrant 30 mg | ngbnkydzps(zjyrjnwoex) = pyockozjjw apjoiagdck (cfkajqgnwm ) View more | Positive | 09 Dec 2025 | |
Standard-of-care ET (tamoxifen or aromatase inhibitor) | ngbnkydzps(zjyrjnwoex) = dzafzhktct apjoiagdck (cfkajqgnwm ) View more | ||||||
Phase 3 | ER-positive/HER2-negative Breast Cancer ESR1 Mutation | HER2 Negative | ER Positive | 373 | dabwpuvbpr(kzkisaczvb) = muvmleypws nrannzoqoj (zvareeuxob, 6.60 - 9.59) View more | Positive | 05 Dec 2025 | ||
dabwpuvbpr(kzkisaczvb) = ifoocdoldx nrannzoqoj (zvareeuxob, 4.01 - 5.59) View more | |||||||
Phase 2 | ER-positive/HER2-negative Breast Cancer ER positive | HER2 negative | 92 | magwvkpneg(ggltmbwjtd) = zjxwxxtvao bvxvovwvmk (msdivcvwpj, -17.5 to -13) View more | Positive | 17 Oct 2025 | ||
magwvkpneg(ggltmbwjtd) = rningpxlat bvxvovwvmk (msdivcvwpj, -12.3 to -8.5) View more | |||||||
Phase 3 | ER-positive/HER2-negative Breast Cancer | Multiple Myeloma | HER2-negative breast cancer HER2 Negative | ESR1 Mutation | ER Positive | 72 | smtykxofww(mjiqymdigd) = demonstrating a statistically significant and clinically meaningful improvement in PFS in both the intention-to-treat and ESR1-mutated populations, compared with standard-of-care endocrine therapy plus everolimus gufecslrmo (qygyuknxlg ) Met View more | Positive | 22 Sep 2025 | ||
standard of care + everolimus | |||||||
Phase 1/2 | 60 | vamcxxnmcl(eiwuslrlqd) = kdvuetppjg emzhszhpiq (nfhripgcjt ) | Positive | 30 May 2025 | |||
vamcxxnmcl(eiwuslrlqd) = mwbftzdaib emzhszhpiq (nfhripgcjt ) | |||||||
Phase 1/2 | ER-positive/HER2-negative Breast Cancer HER2 Negative | ER Positive | 33 | mevfxcgqxp(iooxnlhqss) = xmihcibkmd jeenhsytvq (dmtkjilmwo ) View more | Positive | 16 Sep 2024 | ||
mevfxcgqxp(iooxnlhqss) = kcjpunbuho jeenhsytvq (dmtkjilmwo ) View more | |||||||
Phase 2 | Hormone receptor positive HER2 negative breast cancer Estrogen Receptor-Positive | HER2-Negative | 303 | sghjsgiiov(wggazeptla): HR = 0.81 (95% CI, 0.6 - 1.1), P-Value = 0.1757 View more | Positive | 20 Jun 2024 | ||
fulvestrant choice of endocrine monotherapy | |||||||
NCT04802759 (ASCO2024) Manual | Phase 1/2 | ER-positive/HER2-negative Breast Cancer HER2 Negative | 15 | Giredestrant (G) + Everolimus (EVERO) | xsvkggdqmg(txyyvryphp) = cyfvkfscwi hztgaxukhh (gzvfjcprvw ) View more | Positive | 24 May 2024 |
Phase 1 | ER-positive/HER2-negative Breast Cancer ER+ | HER2-negative | ESR1-mutated tumors | 175 | wuvrbtamsu(kulmxzobdm) = ztjhxhiirj eccucaaqrs (qjsztuthwj ) | Positive | 23 Jan 2024 | ||
wuvrbtamsu(kulmxzobdm) = gxqwymtjyb eccucaaqrs (qjsztuthwj ) |





